JP2013529210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529210A5 JP2013529210A5 JP2013511232A JP2013511232A JP2013529210A5 JP 2013529210 A5 JP2013529210 A5 JP 2013529210A5 JP 2013511232 A JP2013511232 A JP 2013511232A JP 2013511232 A JP2013511232 A JP 2013511232A JP 2013529210 A5 JP2013529210 A5 JP 2013529210A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- halogen
- alkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34568310P | 2010-05-18 | 2010-05-18 | |
| US61/345,683 | 2010-05-18 | ||
| PCT/US2011/036367 WO2011146324A1 (en) | 2010-05-18 | 2011-05-13 | Spiro isoxazoline compounds as sstr5 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013529210A JP2013529210A (ja) | 2013-07-18 |
| JP2013529210A5 true JP2013529210A5 (enExample) | 2014-06-26 |
Family
ID=44991994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511232A Withdrawn JP2013529210A (ja) | 2010-05-18 | 2011-05-13 | Ｓｓｔｒ５アンタゴニストとしてのスピロイソオキサゾリン化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20130040978A1 (enExample) |
| EP (1) | EP2571356A4 (enExample) |
| JP (1) | JP2013529210A (enExample) |
| AR (1) | AR081401A1 (enExample) |
| AU (1) | AU2011256444B2 (enExample) |
| CA (1) | CA2799414A1 (enExample) |
| TW (1) | TW201200524A (enExample) |
| WO (1) | WO2011146324A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8742110B2 (en) | 2010-08-18 | 2014-06-03 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| BR112014030412A2 (pt) | 2012-06-14 | 2017-06-27 | Basf Se | método para combater ou controlar pragas, método para proteger culturas, compostos, processo para a preparação de compostos, uso de um composto, composição agrícola ou veterinária e semente. |
| FR3000064A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes |
| US9605000B2 (en) | 2013-03-14 | 2017-03-28 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists |
| US9663534B2 (en) | 2013-12-17 | 2017-05-30 | Merck Sharp & Dohme Corp. | Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
| CN104945416B (zh) * | 2014-03-24 | 2017-11-17 | 中国科学院上海药物研究所 | 一类螺异噁唑啉衍生物、其制备方法及医药用途 |
| JPWO2015146561A1 (ja) * | 2014-03-26 | 2017-04-13 | 住友精化株式会社 | 臭化芳香族エステル化合物の製造方法 |
| EP3174537B1 (en) * | 2014-07-29 | 2021-06-23 | Merck Sharp & Dohme Corp. | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
| TW201712012A (zh) | 2015-06-16 | 2017-04-01 | 美國禮來大藥廠 | ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物 |
| CN110088089B (zh) | 2016-10-25 | 2023-08-29 | 勃林格殷格翰国际有限公司 | 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途 |
| US10919859B2 (en) | 2017-01-26 | 2021-02-16 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| JP7049349B2 (ja) | 2017-01-26 | 2022-04-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| NZ757081A (en) | 2017-03-16 | 2023-03-31 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| US11608335B2 (en) | 2018-02-12 | 2023-03-21 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| TWI852944B (zh) * | 2018-09-18 | 2024-08-21 | 美商克林提克斯醫藥股份有限公司 | 生長抑制素(somatostatin)調節劑及其用途 |
| TWI841768B (zh) | 2019-08-14 | 2024-05-11 | 美商克林提克斯醫藥股份有限公司 | 非肽生長抑制素(somatostatin)5型受體激動劑及其用途 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| EP4073075A4 (en) * | 2019-12-03 | 2023-12-27 | Kallyope, Inc. | Sstr5 antagonists |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| US11773076B2 (en) | 2021-02-17 | 2023-10-03 | Crinetics Pharmaceuticals, Inc. | Crystalline forms of a somatostatin modulator |
| CN115215787A (zh) * | 2021-04-19 | 2022-10-21 | 中国科学院上海药物研究所 | 生长抑素受体5拮抗剂及其用途 |
| CN116354961B (zh) * | 2021-12-27 | 2025-07-25 | 中国科学院上海药物研究所 | 生长抑素受体5拮抗剂及其药物组合物及用途 |
| CN114230552B (zh) * | 2021-12-29 | 2023-11-03 | 江苏广域化学有限公司 | 三氟甲氧基二苯并噻吩、其制备方法及相关中间体的制备方法 |
| AU2023396827A1 (en) | 2022-12-13 | 2025-06-19 | Crinetics Pharmaceuticals, Inc. | Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof |
| CN115819186B (zh) * | 2023-02-14 | 2023-05-16 | 广东银珠医药科技有限公司 | 一种3,5-二氯苯甲醇的新型制备方法 |
| WO2024204277A1 (ja) | 2023-03-27 | 2024-10-03 | 株式会社スコヒアファーマ | 成長ホルモン分泌促進剤 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5939418A (en) * | 1995-12-21 | 1999-08-17 | The Dupont Merck Pharmaceutical Company | Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors |
| WO1998043962A1 (en) * | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| DE102005044813A1 (de) * | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| CN101253171B (zh) * | 2005-09-02 | 2011-06-15 | 霍夫曼-拉罗奇有限公司 | 苯并噁唑、噁唑并吡啶、苯并噻唑和噻唑并吡啶衍生物 |
| AU2006305620A1 (en) * | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
-
2011
- 2011-05-13 JP JP2013511232A patent/JP2013529210A/ja not_active Withdrawn
- 2011-05-13 AU AU2011256444A patent/AU2011256444B2/en not_active Expired - Fee Related
- 2011-05-13 US US13/641,767 patent/US20130040978A1/en not_active Abandoned
- 2011-05-13 CA CA2799414A patent/CA2799414A1/en not_active Abandoned
- 2011-05-13 WO PCT/US2011/036367 patent/WO2011146324A1/en not_active Ceased
- 2011-05-13 EP EP11783995.1A patent/EP2571356A4/en not_active Withdrawn
- 2011-05-16 TW TW100117097A patent/TW201200524A/zh unknown
- 2011-05-17 AR ARP110101689A patent/AR081401A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503797A5 (enExample) | ||
| JP2011513305A5 (enExample) | ||
| JP2009263394A5 (enExample) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2010502730A5 (enExample) | ||
| JP2014526500A5 (enExample) | ||
| JP2007519649A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2012092103A5 (enExample) | ||
| JP2014530900A5 (enExample) | ||
| JP2015505296A5 (enExample) | ||
| JP2013505969A5 (enExample) | ||
| JP2011521911A5 (enExample) | ||
| JP2014507464A5 (enExample) | ||
| JP2016505637A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2013540712A5 (enExample) | ||
| JP2014507477A5 (enExample) | ||
| WO2010003624A3 (en) | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof | |
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| JP2019527233A5 (enExample) | ||
| JP2012526107A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2010506919A5 (enExample) | ||
| JP2014506582A5 (enExample) |